Role of disease-causing genes in sporadic pancreatic endocrine tumors:: MENI and VHL

被引:62
作者
Moore, PS
Missiaglia, E
Antonello, D
Zamò, A
Zamboni, G
Corleto, V
Falconi, M
Scarpa, A
机构
[1] Univ Verona, Ist Anat Patol, Dipartimento Patol, I-37134 Verona, Italy
[2] Univ Verona, Dept Surg & Gastroenterol Sci, I-37134 Verona, Italy
[3] Univ Roma La Sapienza, Dept Clin Sci, Rome, Italy
关键词
D O I
10.1002/gcc.1180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic endocrine tumors (PETs) occur in association with multiple endocrine neoplasia type I (MEN1) and von Hippel-Lindau (VHL) syndromes caused by germline alterations in MEN1 and VHL, respectively. It is thus expected that these genes will also be altered in a proportion of sporadic PETs. Indeed, MEN1 is altered in about 25% of nonfamilial PETs, although no mutations have been found in VHL. For all clinical subtypes, the frequency of allelic loss on chromosome arm 11q mirrors observed mutational frequencies, with the exception of nonfunctional tumors (NF-PETs), in which mutations have been reported in only 8% of cases. As allelic loss on 11q is the most frequent event found in these neoplasms, this low frequency is somewhat puzzling, particularly in light of the fact that most MEN1-associated PETs are nonfunctioning. To clarify the role of these genes in sporadic PETs, we analyzed 31 sporadic NF-PETs, nine insulinomas, and one VIPoma for alterations in MEN1 and VHL. As somatic mutations were observed in eight (26%) of the NF tumors and in one insulinoma, it would therefore appear unlikely that an additional tumor suppressor gene related to sporadic PET pathogenesis is located on 11q. One insulinoma also had a somatic mutation in VHL, and thus this gene may also be altered in these neoplasms, albeit in a small proportion of cases. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:177 / 181
页数:5
相关论文
共 32 条
[21]   IDENTIFICATION OF THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE [J].
LATIF, F ;
TORY, K ;
GNARRA, J ;
YAO, M ;
DUH, FM ;
ORCUTT, ML ;
STACKHOUSE, T ;
KUZMIN, I ;
MODI, W ;
GEIL, L ;
SCHMIDT, L ;
ZHOU, FW ;
LI, H ;
WEI, MH ;
CHEN, F ;
GLENN, G ;
CHOYKE, P ;
WALTHER, MM ;
WENG, YK ;
DUAN, DSR ;
DEAN, M ;
GLAVAC, D ;
RICHARDS, FM ;
CROSSEY, PA ;
FERGUSONSMITH, MA ;
LEPASLIER, D ;
CHUMAKOV, I ;
COHEN, D ;
CHINAULT, AC ;
MAHER, ER ;
LINEHAN, WM ;
ZBAR, B ;
LERMAN, MI .
SCIENCE, 1993, 260 (5112) :1317-1320
[22]  
Metz David C., 1994, P591
[23]   Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis [J].
Moore, PS ;
Orlandini, S ;
Zamboni, G ;
Capelli, P ;
Rigaud, G ;
Falconi, M ;
Bassi, C ;
Lemoine, NR ;
Scarpa, A .
BRITISH JOURNAL OF CANCER, 2001, 84 (02) :253-262
[24]   Molecular characterization of pancreatic serous microcystic adenomas - Evidence for a tumor suppressor gene on chromosome 10q [J].
Moore, PS ;
Zamboni, G ;
Brighenti, A ;
Lissandrini, D ;
Antonello, D ;
Capelli, P ;
Rigaud, G ;
Falconi, M ;
Scarpa, A .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (01) :317-321
[25]  
Muscarella P, 1998, CANCER RES, V58, P237
[26]   Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables [J].
Pelosi, G ;
Bresaola, E ;
Bogina, G ;
Pasini, F ;
Rodella, S ;
Castelli, P ;
Iacono, C ;
Serio, G ;
Zamboni, G .
HUMAN PATHOLOGY, 1996, 27 (11) :1124-1134
[27]   Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis [J].
Scarpa, A ;
Di Pace, C ;
Talamini, G ;
Falconi, M ;
Lemoine, NR ;
Iacono, C ;
Achille, A ;
Baron, A ;
Zamboni, G .
GUT, 2000, 46 (06) :842-848
[28]   Molecular features of primary mediastinal B-cell lymphoma:: involvement of p16INK4A, p53 and c-myc [J].
Scarpa, A ;
Moore, PS ;
Rigaud, G ;
Inghirami, G ;
Montresor, M ;
Menegazzi, M ;
Todeschini, G ;
Menestrina, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :106-113
[29]  
Shan L, 1998, LAB INVEST, V78, P471
[30]  
Wang EH, 1998, CANCER RES, V58, P4417